Spots Global Cancer Trial Database for asci
Every month we try and update this database with for asci cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI | NCT01266603 | Melanoma | HDIL-2 recMAGE-A3 + AS... | 18 Years - | M.D. Anderson Cancer Center | |
| MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma | NCT00706238 | Melanoma | GSK Biologicals... | 18 Years - | GlaxoSmithKline | |
| GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer | NCT00480025 | Lung Cancer, No... | GSK1572932A Ant... Placebo Control | 18 Years - | GlaxoSmithKline | |
| Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer | NCT00455572 | Lung Cancer, No... | Immunotherapeut... Cisplatin (CDDP... Vinorelbine Radiotherapy | 18 Years - | GlaxoSmithKline | |
| High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI | NCT01266603 | Melanoma | HDIL-2 recMAGE-A3 + AS... | 18 Years - | M.D. Anderson Cancer Center | |
| GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer | NCT00480025 | Lung Cancer, No... | GSK1572932A Ant... Placebo Control | 18 Years - | GlaxoSmithKline | |
| A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor | NCT00796445 | Melanoma | GSK 2132231A Placebo | 18 Years - | GlaxoSmithKline | |
| Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer | NCT00455572 | Lung Cancer, No... | Immunotherapeut... Cisplatin (CDDP... Vinorelbine Radiotherapy | 18 Years - | GlaxoSmithKline | |
| Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer | NCT00455572 | Lung Cancer, No... | Immunotherapeut... Cisplatin (CDDP... Vinorelbine Radiotherapy | 18 Years - | GlaxoSmithKline | |
| A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma | NCT00942162 | Melanoma | Immunotherapeut... | 18 Years - | GlaxoSmithKline | |
| MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma | NCT00706238 | Melanoma | GSK Biologicals... | 18 Years - | GlaxoSmithKline | |
| Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML) | NCT00725283 | Leukaemia, Myel... | GSK Biologicals... | 18 Years - | GlaxoSmithKline | |
| A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients | NCT00849875 | Melanoma | Immunotherapeut... Dacarbazine | 18 Years - | GlaxoSmithKline | |
| A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients | NCT00849875 | Melanoma | Immunotherapeut... Dacarbazine | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
